Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage
biopharmaceutical company with a mission to develop transformative
therapies for people suffering from diseases with high unmet
medical needs, today announced the appointment of Michael W. Kalb,
CPA, as Chief Financial Officer, effective May 10, 2023.
“Michael brings an outstanding track record of
executive leadership in finance, capital raising, business
development and operations management to Impel Pharmaceuticals,”
said Adrian Adams, Chairman of the Board and Chief Executive
Officer of Impel Pharmaceuticals. “We are delighted to welcome
Michael to Impel’s leadership team and believe that his invaluable
expertise will play a major part in the Company’s continued growth
and momentum.”
Mr. Kalb has more than 30 years of experience in
the pharmaceutical and financial service industries. Prior to
joining Impel Pharmaceuticals, he was Executive Vice President
& Chief Financial Officer of CinCor Pharma, Inc., where he
played an integral role in the company’s recent acquisition by
AstraZeneca for up to $1.8 billion. He previously served as Senior
Vice President & Chief Financial Officer of Amarin Corporation
plc, where he contributed to significant revenue growth and
increased market capitalization at peak, and successfully led
multiple financing rounds of both equity and debt raises of varying
size and structure. Prior to Amarin, Mr. Kalb was Group Vice
President & Chief Financial Officer of Taro Pharmaceuticals
Industries, Ltd., and before beginning his tenure in the
pharmaceutical sector, he held roles of increasing seniority and
responsibility at accounting and consulting firms including Huron
Consulting Group, Inc. and Ernst & Young LLP, where he began
his career. He received a B.S. in Business Administration from the
State University of New York, University at Albany, School of
Business.
Mr. Kalb added, “I am thrilled to join Impel’s
accomplished leadership team at such an important time in the
Company’s evolution. I look forward to contributing to the
Company’s continued commercial growth of Trudhesa® and to exploring
additional opportunities to fully leverage the potential of our
proprietary Precision Olfactory Delivery (POD®) technology, with a
focus on ongoing shareholder value creation.”
About Impel
PharmaceuticalsImpel Pharmaceuticals is a commercial-stage
biopharmaceutical company with a mission to develop transformative
therapies for people suffering from diseases with high unmet
medical needs. Impel offers treatments that pair its proprietary
POD® technology with well-established therapeutics. In
September 2021, Impel received U.S. FDA approval for its first
product, Trudhesa® nasal spray, which is approved in the U.S.
for the acute treatment of migraine with or without aura in adults.
In addition to Trudhesa, the Company continues to address patient
needs via licensing and partnerships.
About Impel’s Precision Olfactory
Delivery (POD®) TechnologyImpel’s proprietary POD®
technology is able to deliver a range of therapeutic molecules and
formulations into the vascular-rich upper nasal space, believed to
be a gateway for unlocking the previously unrealized full potential
of these molecules. By delivering predictable doses of drug
directly to the upper nasal space, Impel’s precision performance
technology has the goal of enabling increased and consistent
absorption of drug, overriding the high variability associated with
other nasal delivery systems, yet without the need for an
injection. While an ideal target for drug administration, to date
no technology has been able to consistently deliver drugs to the
upper nasal space. By utilizing this route of administration, Impel
Pharmaceuticals has been able to demonstrate blood concentration
levels for its investigational therapies that are comparable to
intramuscular (IM) administration and can even reach intravenous
(IV)-like systemic levels quickly. Importantly, the POD technology
offers propellant-enabled delivery of dry powder and liquid
formulations that eliminates the need for coordination of
breathing, allowing for self- or caregiver-administration in a
manner that may improve patient outcome, comfort, and potentially,
compliance.
About Trudhesa®
IndicationTrudhesa® is used to treat an active
migraine headache with or without aura in adults. Do not use
Trudhesa to prevent migraine when you have no symptoms. It is not
known if Trudhesa is safe and effective in children.
Important Safety
Information
Serious or potentially life-threatening reductions in blood flow to
the brain or extremities due to interactions between
dihydroergotamine (the active ingredient in Trudhesa) and strong
CYP3A4 inhibitors (such as protease inhibitors and macrolide
antibiotics) have been reported rarely. As a result, these
medications should not be taken together. |
Do not use Trudhesa if you:
- Have any disease affecting your
heart, arteries, or blood circulation.
- Are taking certain anti-HIV
medications known as protease inhibitors (such as ritonavir or
nelfinavir).
- Are taking a macrolide antibiotic
such as clarithromycin or erythromycin.
- Are taking certain antifungals such
as ketoconazole or itraconazole.
- Have taken certain medications such
as triptans or ergot-type medications for the treatment or
prevention of migraine within the last 24 hours.
- Have taken any medications that
constrict your blood vessels or raise your blood pressure.
- Have severe liver or kidney
disease.
- Are allergic to ergotamine or
dihydroergotamine.
Before taking Trudhesa, tell your doctor
if:
- You have high blood pressure, chest
pain, shortness of breath, heart disease; or risk factors for heart
disease (such as high blood pressure, high cholesterol, obesity,
diabetes, smoking, strong family history of heart disease or you
are postmenopausal, or male over 40); or problems with blood
circulation in your arms, legs, fingers, or toes.
- You have or had any disease of the
liver or kidney.
- You are taking any prescription or
over-the-counter medications, including vitamins or herbal
supplements.
- You are pregnant, planning to
become pregnant or are nursing, or have ever stopped medication due
to an allergy or bad reaction.
- This headache is different from
your usual migraine attacks.
The use of Trudhesa should not exceed dosing
guidelines and should not be used on a daily basis. Serious cardiac
(heart) events, including some that have been fatal, have occurred
following the use of dihydroergotamine mesylate, particularly with
dihydroergotamine for injection, but are extremely rare.
You may experience some nasal congestion or
irritation, altered sense of taste, sore throat, nausea, vomiting,
dizziness, and fatigue after using Trudhesa.
Contact your doctor immediately if you
experience:
- Numbness or tingling in your
fingers and toes
- Severe tightness, pain, pressure,
heaviness, or discomfort in your chest
- Muscle pain or cramps in your arms
or legs
- Cold feeling or color changes in
one or both legs or feet
- Sudden weakness
- Slurred speech
- Swelling or itching
The risk information provided here is not
comprehensive. To learn more, talk about Trudhesa with your
healthcare provider or pharmacist. The FDA-approved product
labeling can be found at www.Trudhesa.com or 1-800-555-DRUG. You
can also call 1-833-TRUDHESA (1-833-878-3437) for additional
information.
Cautionary Note on Forward-Looking
StatementsThis press release contains “forward-looking”
statements within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
but not limited to, the potential clinical benefits of Trudhesa®,
the market opportunities of Trudhesa within the migraine market,
the speed of uptake and market growth of Trudhesa, the
effectiveness of the Trudhesa sales force, and Impel’s cash runway.
Forward-looking statements can be identified by words such as:
“believe,” “may,” “will,” “potentially,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “would,” “project,” “plan,”
“expect” or the negative or plural of these words or similar
expressions. These statements are subject to numerous risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including but not limited to,
Impel’s ability to maintain regulatory approval of Trudhesa, its
ability to execute its commercialization strategy for Trudhesa, its
ability to develop, manufacture and commercialize any other product
candidates including plans to address additional indications for
which Impel may pursue regulatory approval, and the effects of
macroeconomic conditions on business operations and any future
clinical programs. Many of these risks are described in greater
detail in Impel’s filings with the Securities and Exchange
Commission. Any forward-looking statements in this press release
speak only as of the date of this press release. Impel assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Impel, POD, Trudhesa and the Impel logo are
registered trademarks of Impel Pharmaceuticals Inc. To learn more
about Impel Pharmaceuticals, please visit our website at
https://impelpharma.com.
Contact:Melyssa WeibleElixir Health Public
RelationsPhone: (1)
201-723-5805Email: mweible@elixirhealthpr.com
Contact:Janhavi MohiteStern Investor
RelationsPhone: 212-362-1200Email: janhavi.mohite@sternir.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Apr 2024 to May 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From May 2023 to May 2024